Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 9/20 | 0.70 |
| ▸ | EGFR | P00533 | 9/20 | 0.70 |
| ▸ | ABL1 | P00519 | 8/20 | 0.70 |
| ▸ | ABL2 | P42684 | 8/20 | 0.70 |
| ▸ | LCK | P06239 | 5/20 | 0.64 |
| ▸ | KDR | P35968 | 5/20 | 0.64 |
| ▸ | TEK | Q02763 | 4/20 | 0.64 |
| ▸ | LYN | P07948 | 2/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | RGS12 | O14924 | 1/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | GMNN | O75496 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 1/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.64 |
| ▸ | FYN | P06241 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6870684 | 0.87 | SRC (0.77) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL7006750 | 0.86 | SRC (0.61) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL23847632 | 0.86 | SRC (0.76) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL19973965 | 0.84 | SRC (0.64) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL7005371 | 0.84 | TEK (0.61) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL16709456 | 0.84 | RET (0.59) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL2075710 | 0.84 | SRC (0.63) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL5936173 | 0.82 | SRC (0.97) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL132510 | 0.81 | SRC (1.00) | SRCEGFRABL1ABL2LCK | |
| SCHEMBL18044650 | 0.80 | RET (0.55) | SRCEGFRABL1ABL2LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190255056-A1 | A HCK INHIBITOR AND A BCL-2 INHIBITOR FOR TREATING ACUTE MYELOID LEUKEMIA | RIKEN (JP) | 2019-08-22 | — | — | US | disclosed |
| US-20190255056-A1 | A HCK INHIBITOR AND A BCL-2 INHIBITOR FOR TREATING ACUTE MYELOID LEUKEMIA | RIKEN (JP) | 2019-08-22 | — | — | US | disclosed |
| EP-3512555-A1 | A HCK INHIBITOR AND A BCL-2 INHIBITOR FOR TREATING ACUTE MYELOID LEUKEMIA | Riken (JP) | 2019-07-24 | — | — | EP | disclosed |
| WO-2018052120-A1 | A HCK INHIBITOR AND A BCL-2 INHIBITOR FOR TREATING ACUTE MYELOID LEUKEMIA | RIKEN (JP) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190255056-A1 | A HCK INHIBITOR AND A BCL-2 INHIBITOR FOR TREATING ACUTE MYELOID LEUKEMIA | MCL1, HCK, FLT3 | SRC 147/4885EGFR 310/4885ABL1 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.